Literature DB >> 22012651

Off-label prescribing in macular degeneration.

Margaret McCartney1.   

Abstract

Mesh:

Substances:

Year:  2011        PMID: 22012651     DOI: 10.1136/bmj.d6778

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  3 in total

1.  Bevacizumab versus ranibizumab: why are we not playing the joker?

Authors:  Roberto Banfi; Francesco Attanasio; Nadia Palazzi; Silvia Colombini; Tiziana Falai; Michele Cecchi; Gianni Virgili
Journal:  Int J Clin Pharm       Date:  2013-08

Review 2.  The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review.

Authors:  John A Ford; Andrew Elders; Deepson Shyangdan; Pamela Royle; Norman Waugh
Journal:  BMJ       Date:  2012-08-13

Review 3.  Ranibizumab versus bevacizumab for ophthalmic diseases related to neovascularisation: a meta-analysis of randomised controlled trials.

Authors:  Bin Wu; Haixiang Wu; Xiaoyan Liu; Houwen Lin; Jin Li
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.